Citigroup’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.09M | Sell |
214,747
-444,702
| -67% | -$2.25M | ﹤0.01% | 2478 |
|
|
2025
Q1 | $3.49M | Buy |
659,449
+158,461
| +32% | +$838K | ﹤0.01% | 1683 |
|
|
2024
Q4 | $3.39M | Buy |
500,988
+310,236
| +163% | +$2.1M | ﹤0.01% | 1739 |
|
|
2024
Q3 | $1.26M | Buy |
190,752
+87,142
| +84% | +$574K | ﹤0.01% | 2394 |
|
|
2024
Q2 | $777K | Sell |
103,610
-697,577
| -87% | -$5.23M | ﹤0.01% | 2410 |
|
|
2024
Q1 | $7.99M | Buy |
801,187
+396,334
| +98% | +$3.95M | 0.01% | 1000 |
|
|
2023
Q4 | $3.99M | Sell |
404,853
-65,659
| -14% | -$647K | ﹤0.01% | 1242 |
|
|
2023
Q3 | $3.6M | Buy |
470,512
+293,174
| +165% | +$2.24M | ﹤0.01% | 1176 |
|
|
2023
Q2 | $1.32M | Sell |
177,338
-510,887
| -74% | -$3.82M | ﹤0.01% | 2025 |
|
|
2023
Q1 | $4.59M | Buy |
688,225
+455,398
| +196% | +$3.04M | ﹤0.01% | 1149 |
|
|
2022
Q4 | $1.8M | Buy |
232,827
+71,267
| +44% | +$549K | ﹤0.01% | 1594 |
|
|
2022
Q3 | $1.72M | Buy |
161,560
+149,260
| +1,213% | +$1.59M | ﹤0.01% | 1709 |
|
|
2022
Q2 | $100K | Sell |
12,300
-2,599
| -17% | -$21.1K | ﹤0.01% | 3554 |
|
|
2022
Q1 | $106K | Sell |
14,899
-229,458
| -94% | -$1.63M | ﹤0.01% | 3700 |
|
|
2021
Q4 | $4.19M | Buy |
244,357
+199,063
| +439% | +$3.41M | ﹤0.01% | 1391 |
|
|
2021
Q3 | $1.04M | Buy |
45,294
+44,288
| +4,402% | +$1.02M | ﹤0.01% | 2362 |
|
|
2021
Q2 | $37K | Buy |
+1,006
| New | +$37K | ﹤0.01% | 4289 |
|